DYN
Dyne Therapeutics, Inc.$18.19+0.25 (+1.39%)Prev Close$17.95·MCap$2.97B·P/E—·Vol577.1K·Yield—
▲
Buys (12M)
8
$1.19M
▼
Sells (12M)
23
$54.90M
◆
Net Activity
Net Seller
$53.72M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Dyne Therapeutics, Inc. (DYN) has been dominated by selling, with 8 insider purchases totaling $1.19M and 23 insider sales totaling $54.90M. The most recent insider transaction was by Posner Brian S (director), who purchased $33.9K worth of shares on Jun 9, 2026. Dyne Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.97B.
DYN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Posner Brian S | director | Buy | 2,000 | $16.94 | $33.9K | 24,500 |
| Jun 5, 2026 | Posner Brian S | director | Buy | 2,500 | $17.48 | $43.7K | 22,500 |
| May 28, 2026 | Posner Brian S | director | Buy | 2,000 | $18.21 | $36.4K | 20,000 |
| May 22, 2026 | Posner Brian S | director | Buy | 2,500 | $17.12 | $42.8K | 18,000 |
| May 14, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,564 | $18.36 | $28.7K | 170,042 |
| May 14, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 228 | $18.36 | $4.2K | 154,353 |
| May 14, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,448 | $18.36 | $26.6K | 123,925 |
| May 14, 2026 | Cox John | director, officer: CEO & President | Sell | 3,311 | $18.36 | $60.8K | 370,834 |
| May 6, 2026 | Rhodes Jason P | director | Sell | 106,723 | $18.14 | $1.94M | 4,933,196 |
| Apr 30, 2026 | Rhodes Jason P | director | Sell | 227,337 | $18.38 | $4.18M | 4,939,489 |
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
| Jun 6, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 146 | $13.35 | $1.9K | 95,911 |
| Jun 6, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,342 | $13.35 | $17.9K | 92,815 |
| Mar 13, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,153 | $11.38 | $24.5K | 195,840 |
| Mar 13, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 143 | $12.12 | $1.7K | 96,057 |
| Mar 13, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,343 | $11.38 | $15.3K | 122,330 |
| Mar 7, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 1,094 | $11.83 | $12.9K | 197,993 |
| Mar 7, 2025 | Cox John | CEO & President | Sell | 4,061 | $11.83 | $48.0K | 146,239 |
| Mar 7, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,343 | $11.83 | $15.9K | 94,157 |
| Mar 7, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 917 | $11.83 | $10.8K | 123,673 |
| Feb 25, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,598 | $13.95 | $36.2K | 199,087 |
| Feb 18, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,488 | $13.95 | $34.7K | 124,590 |
| Dec 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,334 | $28.12 | $65.6K | 201,685 |
| Dec 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,455 | $28.12 | $40.9K | 127,078 |
| Dec 10, 2024 | Kersten Dirk | Sell | 136,112 | $29.30 | $3.99M | 5,434,982 | |
| Dec 6, 2024 | Kersten Dirk | Sell | 138,845 | $29.38 | $4.08M | 5,540,463 | |
| Dec 4, 2024 | Kersten Dirk | Sell | 110,933 | $29.50 | $3.27M | 5,706,462 | |
| Nov 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,856 | $28.20 | $80.5K | 137,519 |
| Nov 18, 2024 | Incerti Carlo | Sell | 16,500 | $28.73 | $474.0K | 0Exit |
Showing 1–50 of 181
1 / 4
DYN Insider Buying Activity
The following table shows recent insider purchases of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Posner Brian S | director | Buy | 2,000 | $16.94 | $33.9K | 24,500 |
| Jun 5, 2026 | Posner Brian S | director | Buy | 2,500 | $17.48 | $43.7K | 22,500 |
| May 28, 2026 | Posner Brian S | director | Buy | 2,000 | $18.21 | $36.4K | 20,000 |
| May 22, 2026 | Posner Brian S | director | Buy | 2,500 | $17.12 | $42.8K | 18,000 |
| Apr 1, 2026 | Posner Brian S | director | Buy | 2,000 | $17.08 | $34.2K | 15,500 |
| Mar 13, 2026 | Posner Brian S | director | Buy | 2,000 | $19.35 | $38.7K | 13,500 |
| Mar 10, 2026 | Posner Brian S | director | Buy | 3,000 | $15.06 | $45.2K | 11,500+35% |
| Jul 15, 2025 | Cox John | CEO & President | Buy | 100,000 | $9.11 | $911.0K | 242,179+70% |
DYN Insider Selling Activity
The following table shows recent insider sales of Dyne Therapeutics, Inc. (DYN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 1,564 | $18.36 | $28.7K | 170,042 |
| May 14, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 228 | $18.36 | $4.2K | 154,353 |
| May 14, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 1,448 | $18.36 | $26.6K | 123,925 |
| May 14, 2026 | Cox John | director, officer: CEO & President | Sell | 3,311 | $18.36 | $60.8K | 370,834 |
| May 6, 2026 | Rhodes Jason P | director | Sell | 106,723 | $18.14 | $1.94M | 4,933,196 |
| Apr 30, 2026 | Rhodes Jason P | director | Sell | 227,337 | $18.38 | $4.18M | 4,939,489 |
| Apr 27, 2026 | Rhodes Jason P | director | Sell | 384,549 | $18.47 | $7.10M | 5,221,857 |
| Apr 23, 2026 | Kersten Dirk | director | Sell | 10,952 | $20.01 | $219.2K | 4,199,225 |
| Apr 22, 2026 | Rhodes Jason P | director | Sell | 834,302 | $19.75 | $16.48M0.5% OS | 5,554,904 |
| Apr 21, 2026 | Kersten Dirk | director | Sell | 337,248 | $20.21 | $6.82M | 4,332,799 |
| Apr 17, 2026 | Kersten Dirk | director | Sell | 99,613 | $20.35 | $2.03M | 4,562,546 |
| Apr 3, 2026 | Lucera Erick | officer: Chief Financial Officer | Sell | 5,727 | $18.64 | $106.8K | 125,373 |
| Mar 13, 2026 | Kersten Dirk | director | Sell | 129,672 | $19.52 | $2.53M | 4,644,386 |
| Mar 11, 2026 | Kersten Dirk | director | Sell | 688,788 | $19.09 | $13.15M | 5,285,156 |
| Mar 6, 2026 | Cox John | director, officer: CEO & President | Sell | 2,732 | $14.90 | $40.7K | 374,145 |
| Mar 6, 2026 | Friedl-Naderer Johanna | officer: Chief Commercial Officer | Sell | 148 | $14.90 | $2.2K | 154,581 |
| Mar 6, 2026 | Kerr Douglas | officer: Chief Medical Officer | Sell | 904 | $14.90 | $13.5K | 171,606 |
| Dec 5, 2025 | Cox John | CEO & President | Sell | 2,662 | $20.72 | $55.2K | 196,877 |
| Dec 5, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 144 | $20.72 | $3.0K | 94,729 |
| Dec 5, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 880 | $20.72 | $18.2K | 87,510 |
| Sep 9, 2025 | Cox John | CEO & President | Sell | 2,640 | $13.41 | $35.4K | 199,539 |
| Sep 8, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 1,038 | $13.29 | $13.8K | 95,017 |
| Sep 8, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 4,425 | $13.30 | $58.8K | 89,263 |
| Jun 6, 2025 | Cox John | CEO & President | Sell | 4,060 | $13.35 | $54.2K | 142,179 |
| Jun 6, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 146 | $13.35 | $1.9K | 95,911 |
| Jun 6, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,342 | $13.35 | $17.9K | 92,815 |
| Mar 13, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,153 | $11.38 | $24.5K | 195,840 |
| Mar 13, 2025 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | 143 | $12.12 | $1.7K | 96,057 |
| Mar 13, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,343 | $11.38 | $15.3K | 122,330 |
| Mar 7, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 1,094 | $11.83 | $12.9K | 197,993 |
| Mar 7, 2025 | Cox John | CEO & President | Sell | 4,061 | $11.83 | $48.0K | 146,239 |
| Mar 7, 2025 | Kerr Douglas | Chief Medical Officer | Sell | 1,343 | $11.83 | $15.9K | 94,157 |
| Mar 7, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 917 | $11.83 | $10.8K | 123,673 |
| Feb 25, 2025 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,598 | $13.95 | $36.2K | 199,087 |
| Feb 18, 2025 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 2,488 | $13.95 | $34.7K | 124,590 |
| Dec 11, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,334 | $28.12 | $65.6K | 201,685 |
| Dec 11, 2024 | Scalzo Richard William | SVP, Head of Finance & Admin. | Sell | 1,455 | $28.12 | $40.9K | 127,078 |
| Dec 10, 2024 | Kersten Dirk | Sell | 136,112 | $29.30 | $3.99M | 5,434,982 | |
| Dec 6, 2024 | Kersten Dirk | Sell | 138,845 | $29.38 | $4.08M | 5,540,463 | |
| Dec 4, 2024 | Kersten Dirk | Sell | 110,933 | $29.50 | $3.27M | 5,706,462 | |
| Nov 18, 2024 | Beskrovnaya Oxana | Chief Scientific Officer | Sell | 2,856 | $28.20 | $80.5K | 137,519 |
| Nov 18, 2024 | Incerti Carlo | Sell | 16,500 | $28.73 | $474.0K | 0Exit |
DYN Insiders
Similar Stocks to DYN
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B